New Stock News | Orin Bio (688319.SH) submits its second listing application to the Hong Kong Stock Exchange

According to the Zhitong Finance App, it was revealed by the Hong Kong Stock Exchange on June 30th that Chengdu Ouline Biotech Co., Ltd. (referred to as Ouline Biotech, 688319.SH) has submitted an application for listing on the main board of the Hong Kong Stock Exchange for the second time. China Citic Securities is its exclusive sponsor. The prospectus shows that Ouline Biotech is a biopharmaceutical company dedicated to the research, development, production, and commercialization of innovative vaccines. The company has established a systematic product development framework, focusing on key research and development areas, and managing research and development projects in different development stages. The company's strategic focus is on the two core areas of "super bacteria vaccines" and "adult vaccines." Since its establishment, Ouline Biotech has built a comprehensive production and quality management system, and has established a wide sales network covering 30 provinces, municipalities, and autonomous regions in China.